The administration of sorbents plays a vital role in reducing systemic toxicity after radionuclides or harmful chemicals enter the organism. This study explores the pharmacological characteristics of the newly developed ferrocyanide-bentonite sorbent, Ferbensorb. As a composite formulation, Ferbensorb integrates potassium-iron(III) hexacyanoferrate(II), bentonite, gelatin, along with a mixture of essential macro- and microelements. Experimental assessments were performed using mice and rats as animal models. The investigation evaluated its cesium sorption efficacy, strontium radionuclide retention capability, and performance under simulated associative mycotoxicosis. Autopsies were conducted to assess anatomical alterations, while variations in overall body mass and the condition of specific internal organs were documented. Blood analyses also included profiling of the leukocyte formula. The findings demonstrated that the ferrocyanide-bentonite sorbent, Ferbensorb, effectively alleviated both structural and functional disruptions induced by mycotoxins, including ochratoxin A, fumonisin B, and zearalenone. Improvements were observed in weight gain, innate immune response (indicated by a higher proportion of neutrophils), enhanced serum lysozyme and bactericidal activities, and increased survival rates in the treated animals.
This paper presents the findings of multiple investigations into the newly developed Bentorb sorbent, derived from winemaking byproducts, specifically the adhesive residues of yellow blood salt. Elemental analysis revealed that the predominant components of Bentorb include oxygen, carbon, silicon, aluminum, iron, nitrogen, and magnesium, which together make up the majority of the sorbent’s composition. Toxicological assessments of Bentorb were conducted using laboratory animals. To evaluate acute toxicity, 60 white mongrel rats, each weighing approximately 237 ± 7 g, were subjected to the substance. The results showed no significant changes in the general clinical condition of rats in either the experimental or control groups, and all animals survived the tests. Chronic toxicity was assessed in 60 white mice and 40 Wistar rats, each weighing 185 ± 12 g. Over the study period, no notable differences in health or survival rates were observed between the experimental and control groups. The effects of Bentorb on gastrointestinal function were examined in piglets aged 40-80 days. Additionally, the potential embryotoxicity of Bentorb was investigated in pregnant Wistar rats weighing 200-240 g. The study also included analyses of body weight and various internal organs in both control and experimental groups that received Bentorb.
Eurasian Academy of Medicine and Dentistry